Skip to main content

Table 1 Characteristics of the included studies

From: Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

Study

Phase

Treatment status

HER-2 therapy

Pts no.

Dosage

Chemotherapy

Efficacy endpoint

Patients status

Luca Gianni 2018 [22]

2

Neoadjuvant

P + T

30

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

Palbociclib, Fulvestrant

pCR

safety

Unilateral invasive, HER2-positivebreast cancer

Julia Foldi 2017 [23]

2

Neoadjuvant

P + T

48

During weeks 1–12, 840 mg → 420 mg q3w + 4 mg/kg → 2 mg/Kg weekly;

During weeks 13–24, 420 mg + 6 mg/kg q3w;

Paclitaxel, FEC

pCR

safety

stage I–III, HER2-positive invasive breast cancer

JASMEET C. SINGH 2017 [24]

retrospective study

Neoadjuvant

P + T

57

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

AC, Paclitaxel

pCR

operable breast cancer (53)

locally advanced disease(3)

inflammatory breast cancer(1)

Shruti R. Tiwari 2016 [25]

retrospective study

Neoadjuvant

P + T

70

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

Docetaxel, Carboplatin

pCR

safety

I(6), II(48), and III(16), HER2-positive breast cancer

MICHAEL ANDERSSON 2017 [26]

2

Metastatic

P + T

107

co-infusion of 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

Vinorelbine

PFS

safety

HER2-positive MBC/LABC

Edith A. Perez 2016 [27]

2

Metastatic

P + T

106

Infusion of 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w, respectively

Vinorelbine

PFS

safety

HER2-positive MBC/LABC

Chau Dang 2015 [28]

2

Metastatic

P + T

69

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

Docetaxel

PFS

safety

HER2-positive MBC

Bao D Dao 2015 [29]

retrospective study

Metastatic

P + T

19

NK

Taxane

PFS

HER2-positive MBC

Kazuhiro Araki 2017 [14]

2

Metastatic

P + T

30

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

Eribulin

PFS

safety

HER2-positive ABC

Jose´ Baselga 2010 [30]

2

Metastatic

P + T

66

840 mg → 420 mg q3w + 4 mg/kg → 2 mg/kg weekly or 8 mg/kg → 6 mg/kg q3w

NO

PFS

safety

HER2-positive MBC

Chia C. Portera 2008 [31]

1

Metastatic

P + T

11

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

NO

safety

HER2-positive MBC

Nicholas J. Robert 2017 [32]

retrospective study

Metastatic

P + T

266

NK

Taxane

PFS

safety

HER2-positive MBC

Sabino De Placido 2018 [33]

retrospective study

Metastatic

P + T

155

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

Taxane

PFS

safety

HER2-positive MBC

Kathy D. Miller 2014 [34]

Ib/IIa

Metastatic

P + T-DM1

64

840 mg → 420 mg q3w + 3.6 mg/kg q3w

NO

PFS

safety

HER2-positive MBC/LABC

Peter Beitsch 2017 [10]

prospective

Neoadjuvant

A:P + T

B:T

119

178

NK

Docetaxel, Carboplatin

pCR

T4 or inflammatory HER2-positive breast cancer

Luca Giannia 2012 [15]

2

Neoadjuvant

A:P + T

B:T

107

107

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w

Docetaxel

pCR

safety

locally advanced, inflammatory, or early-stage HER2-positive breast cancer

Gunter von Minckwitz 2017 [16]

prospective

Adjuvant

A:P + T

B:T

2400

2405

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w

FEC, Docetaxel or Paclitaxel, Carboplatin

safety

HER2-Positive EBC

Rashmi K. Murthy 2018 [17]

retrospective study

Neoadjuvant

A:P + T

B:T

170

807

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w or 4 mg/kg → 2 mg/kg weekly

Paclitaxel

pCR

Stage II-III,HER-2-positive Breast Cancer

M. Martin 2016 [13]

I b /IIa

Metastatic

A:P + T-DM1

B:T-DM1

33

40

840 mg → 420 mg q3w + 3.6 mg/kg q3w

3.6 mg/kg q3w

Docetaxel

pCR

safety

HER2-positive MBC/LABC

Mothaffar Rimawi 2017 [18]

2

Metastatic

A:P + T

B:T

129

129

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w

AI

PFS

safety

HER2-positive MBC/LABC

Ander Urruticoecheaa 2017 [9]

3

Metastatic

A:P + T

B:T

228

224

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w

Carboplatin

PFS

safety

HER2-positive MBC

Sandra M. Swaina 2015 [19]

3

Metastatic

A:P + T

B:T

402

406

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w

Docetaxel

PFS

safety

HER2-positive MBC

Ian E. Kropa 2016 [20]

I b /IIa

Metastatic

A:P + T-DM1

B:T-DM1

22

22

840 mg → 420 mg q3w + 3.6 mg/kg q3w or 2.4 mg/kg weekly

3.6 mg/kg q3w or 2.4 mg/kg weekly

Paclitaxel

PFS

safety

HER2-positive MBC/LABC

Edith A. Pereza 2017 [21]

3

Metastatic

A:P + T-DM1

B:T-DM1

363

367

840 mg → 420 mg q3w + 3.6 mg/kg q3w

3.6 mg/kg q3w

NO

PFS

safety

HER2-positive MBC/LABC

Manish Gupta 2013 [11]

2

Metastatic

A:P + T-DM1

B:T-DM1

20

51

840 mg → 420 mg q3w + 3.6 mg/kg q3w

3.6 mg/kg q3w

NO

PFS

safety

HER2-positive MBC/LABC

Nadia Hussain 2018 [35]

retrospective study

Neoadjuvant

A:P + T

B:T

22

23

840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w

8 mg/kg → 6 mg/kg q3w

Docetaxel, Carboplatin

safety

stages 1–3 HER2-positive breast cancer

  1. Abbreviations: T Trastuzumab, P Pertuzumab, T-DM1 Trastuzumab emtansine, AC Doxorubicin, Cyclophosphamide, FEC Fluorouracil (5FU), Epirubicin, and Cyclophosphamide, AI Aromatase Inhibitor, pts no patients number, mg milligram, kg kilogram, q3w three-weekly, NK unknown, NO without chemotherapy, ABC Advanced Breast Cancer, MBC Metastatic Breast Cancer, LABC Locally Advanced Breast Cancer, EBC Early Breast Cancer, HER2 Human Epidermal Growth Factor Receptor 2
  2. a randomized controlled trials